GYO18, 2023 Flashcards
1
Q
What is the study question of GYO18?
A
Pembrolizumab vs placebo to the standard chemotherapy backbone
2
Q
Results of GYO18?
A
At 12 mo for MMRd, PFS 74% vs 38% favoring pembro
13 vs 8.7 mo for MMRp with 46% lower risk of PD or death
G3+ adverse events were higher in the pembro groups
2y GYO18; 3y RUBY